Impact of the KIT/PDGFRA genotype on prognosis in imatinib-naive Japanese patients with gastrointestinal stromal tumor.

ABSTRACT:

Background

Most gastrointestinal stromal tumors (GIST) harbor a mutation in KIT or platelet-derived growth factor receptor alfa (PDGFRA). Although genotyping is a useful predictive marker of tyrosine kinase inhibitors, whether it can predict prognosis remains controversial.

Methods

Data on 402 patients with GIST who underwent macroscopically complete surgery and received no neoadjuvant/adjuvant therapy were selected from a prospective GIST database at the three, participating hospitals. The types and locations of KIT and PDGFRA mutations were analyzed by direct sequencing of the amplified genes. The association between the genotypic characteristics and prognosis was then examined.

Results

Tumor genotypes were analyzed in 398 of 402 (99%) pa

SUBMITTER: Cho H 

PROVIDER: S-EPMC8889858 | biostudies-literature | 2022 Mar

REPOSITORIES: biostudies-literature